Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth I Berger

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
American Journal of Medical Genetics. Part A|February 4, 2005
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)Stuart J Swiedler, Michael Beck, Manal Bajbouj, et al.
Journal of Occupational and Environmental Medicine|June 9, 2015
Systemic Inflammation Associated With World Trade Center Dust Exposures and Airway Abnormalities in the Local CommunityAngeliki Kazeros, Enhan Zhang, Xin Cheng, et al.
Chest|October 13, 2009
Obstructive airways disease with air trapping among firefighters exposed to World Trade Center dustMichael D Weiden, Natalia Ferrier, Anna Nolan, et al.
The Journal of Pediatrics|May 2, 2006
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyPaul Harmatz, Roberto Giugliani, Ida Schwartz, et al.
Journal of Occupational and Environmental Medicine|April 15, 2009
Characteristics of a residential and working community with diverse exposure to World Trade Center dust, gas, and fumesJoan Reibman, Mengling Liu, Qinyi Cheng, et al.
Molecular Genetics and Metabolism|July 7, 2016
Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndromeChristian J Hendriksz, Rossella Parini, Moeenaldeen D AlSayed, et al.
Orphanet Journal of Rare Diseases|January 30, 2022
Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathyManisha Korb, Allison Peck, Lindsay N Alfano, et al.
BMC Cardiovascular Disorders|April 17, 2026
Uncovering the gene variants in a global cohort of patients with unexplained increased left ventricular wall thickness using next-generation sequencingMichael Arad, Andrea Virginia Ferreira Chaves, Murillo Antunes, et al.
Journal of Inherited Metabolic Disease|February 9, 2010
Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatasePaul Harmatz, Zi-Fan Yu, Roberto Giugliani, et al.
The European Respiratory Journal|November 28, 2019
Technical standards for respiratory oscillometryGregory G King, Jason Bates, Kenneth I Berger, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
American Journal of Medical Genetics. Part A|February 4, 2005
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)Stuart J Swiedler, Michael Beck, Manal Bajbouj, et al.
Journal of Occupational and Environmental Medicine|June 9, 2015
Systemic Inflammation Associated With World Trade Center Dust Exposures and Airway Abnormalities in the Local CommunityAngeliki Kazeros, Enhan Zhang, Xin Cheng, et al.
Chest|October 13, 2009
Obstructive airways disease with air trapping among firefighters exposed to World Trade Center dustMichael D Weiden, Natalia Ferrier, Anna Nolan, et al.
The Journal of Pediatrics|May 2, 2006
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyPaul Harmatz, Roberto Giugliani, Ida Schwartz, et al.
Journal of Occupational and Environmental Medicine|April 15, 2009
Characteristics of a residential and working community with diverse exposure to World Trade Center dust, gas, and fumesJoan Reibman, Mengling Liu, Qinyi Cheng, et al.
Molecular Genetics and Metabolism|July 7, 2016
Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndromeChristian J Hendriksz, Rossella Parini, Moeenaldeen D AlSayed, et al.
Orphanet Journal of Rare Diseases|January 30, 2022
Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathyManisha Korb, Allison Peck, Lindsay N Alfano, et al.
BMC Cardiovascular Disorders|April 17, 2026
Uncovering the gene variants in a global cohort of patients with unexplained increased left ventricular wall thickness using next-generation sequencingMichael Arad, Andrea Virginia Ferreira Chaves, Murillo Antunes, et al.
Journal of Inherited Metabolic Disease|February 9, 2010
Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatasePaul Harmatz, Zi-Fan Yu, Roberto Giugliani, et al.
The European Respiratory Journal|November 28, 2019
Technical standards for respiratory oscillometryGregory G King, Jason Bates, Kenneth I Berger, et al.
Pageof 11